Koul H K, Kumar B, Koul S, Deb A A, Hwa J S, Maroni P, van Bokhoven A, Lucia M S, Kim F J, Meacham R B
Division of Urology, Department of Surgery, University of Colorado at Denver School of Medicine, Aurora, Colorado 80045, USA.
Drugs Today (Barc). 2010 Dec;46(12):929-43. doi: 10.1358/dot.2010.46.12.1537942.
It is currently estimated that infections and inflammatory responses are linked to 15-20% of all deaths from cancer worldwide. Many studies point to an important role of inflammation in prostate growth, although the contribution of inflammation to benign prostatic hyperplasia and prostate cancer is not completely understood. There is an unmet need for epidemiologic and molecular pathologic approaches to address the issue of inflammation and prostate cancer. Here we review the published evidence with respect to the involvement of inflammation and infection in prostate cancer. We also present an overarching hypothesis that chronic inflammation associated with aging and infection may play an important role in the etiology and progression of prostate cancer. As such, chronic inflammation may represent an important therapeutic target in prostate cancer.
目前估计，感染和炎症反应与全球所有癌症死亡病例的15%至20%相关。许多研究指出炎症在前列腺生长中起重要作用，尽管炎症对良性前列腺增生和前列腺癌的影响尚未完全明确。在解决炎症与前列腺癌问题方面，流行病学和分子病理学方法仍存在未满足的需求。在此，我们回顾已发表的关于炎症和感染与前列腺癌关系的证据。我们还提出一个总体假设，即与衰老和感染相关的慢性炎症可能在前列腺癌的病因和进展中起重要作用。因此，慢性炎症可能是前列腺癌的一个重要治疗靶点。
